GlassScriptPhysician profile
Bruce L Fisher
NPI 1508854266
$2,500.20
in general payments reported to CMS, 2019-2025
23 companies · $417 in 2025
The $417 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $179 · 2021: $79.65 · 2022: $268 · 2023: $349 · 2024: $605 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.36 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $595.65 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $366.61 | 2019-2025 | |
| Boston Scientific Corporation | $261.06 | 2023-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| E.R. Squibb & Sons, L.L.C. | $190.42 | 2020-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $180.54 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $132.77 | 2019-2024 | Brilinta, Farxiga |
| Pfizer INC. | $126.19 | 2019-2025 | |
| Genzyme Corporation | $125.00 | 2019 | |
| Medtronic, INC. | $122.61 | 2022 | |
| Vital Connect, INC | $65.54 | 2023-2025 | Vitalpatch Rtm |
| Sanofi-Aventis U.S. LLC | $51.68 | 2019 | |
| Abbott Laboratories | $47.44 | 2021-2022 | |
| Esperion Therapeutics, INC. | $40.94 | 2023-2024 | Nexletol |
| Novo Nordisk INC | $37.72 | 2020 | |
| Baxter Healthcare | $35.24 | 2024 | Hillrom - Carnation Ambulatory Monitor |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $20.96 | 2025 | |
| Kestra Medical Technology Services, INC. | $20.84 | 2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $17.78 | 2025 | Onpattro |
| Merck Sharp & Dohme LLC | $13.28 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.23 | 2022 | |
| Braemar Manufacturing, LLC | $11.92 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.44 | 2019 | |
| Amarin Pharma, INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Fisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.